GSA Capital Partners LLP Purchases New Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

GSA Capital Partners LLP acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 826 shares of the company’s stock, valued at approximately $276,000.

Several other hedge funds and other institutional investors also recently modified their holdings of MEDP. Westwind Capital raised its position in Medpace by 800.1% in the second quarter. Westwind Capital now owns 380,929 shares of the company’s stock worth $156,886,000 after acquiring an additional 338,610 shares in the last quarter. Clearbridge Investments LLC grew its stake in shares of Medpace by 55.1% during the 2nd quarter. Clearbridge Investments LLC now owns 403,892 shares of the company’s stock worth $166,343,000 after purchasing an additional 143,481 shares during the period. Renaissance Technologies LLC grew its stake in shares of Medpace by 38.3% during the 2nd quarter. Renaissance Technologies LLC now owns 443,588 shares of the company’s stock worth $182,692,000 after purchasing an additional 122,800 shares during the period. AQR Capital Management LLC increased its holdings in shares of Medpace by 62.3% in the 2nd quarter. AQR Capital Management LLC now owns 310,650 shares of the company’s stock valued at $127,941,000 after purchasing an additional 119,257 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Medpace by 1,028.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 116,683 shares of the company’s stock valued at $48,056,000 after purchasing an additional 106,343 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Performance

MEDP stock opened at $337.75 on Friday. The company has a 50 day moving average price of $340.14 and a two-hundred day moving average price of $373.33. The stock has a market capitalization of $10.50 billion, a P/E ratio of 29.58, a PEG ratio of 1.89 and a beta of 1.37. Medpace Holdings, Inc. has a one year low of $268.80 and a one year high of $459.77.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating the consensus estimate of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The company had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. During the same quarter in the previous year, the business earned $2.22 EPS. The firm’s revenue was up 8.3% on a year-over-year basis. Research analysts forecast that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

MEDP has been the subject of a number of research analyst reports. Redburn Atlantic assumed coverage on shares of Medpace in a report on Monday, October 14th. They issued a “buy” rating and a $404.00 target price for the company. TD Cowen reduced their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Robert W. Baird lowered Medpace from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $413.00 to $349.00 in a report on Wednesday, October 23rd. UBS Group downgraded Medpace from a “buy” rating to a “neutral” rating and cut their price target for the stock from $420.00 to $350.00 in a research note on Friday, September 27th. Finally, StockNews.com cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $380.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.